Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study

Overview

Localized scleroderma or morphea is a fibrotic disease, imiquimod induces cytokines which inhibit fibrotic activity . We propose that topical imiquimod 5% cream is efficacious and safe in treating plaque-type morphea. Twenty adults will be enrolled for a pilot study. A screening and baseline clinic visit will be required for each patient enrolled in the study. Each visit will involve completing a medical history, skin examination, digital pictures, histologic examination if the patient consents and an ultrasonographic score. One morphea plaque will be treated with topical imiquimod 5% cream, and another morphea lesion with vehicle cream. Patients will be asked about side effects (local and systemic). Patients will be followed up in the clinic at 3, 6 and 9 months of therapy, and 3 months following end of treatment period (month 12).

Full Title of Study: “Evaluation of the Efficacy and Safety of Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)

Interventions

  • Drug: imiquimod 5% cream (Aldara)

Clinical Trial Outcome Measures

Primary Measures

  • The main outcome of this study is to evaluate the efficacy of imiquimod cream in improving morphea plaques. Improvement of skin induration will be measured by percent improvement in the skin induration as assessed radiologically by ultrasonography score.

Secondary Measures

  • Any adverse outcome is recorded.

Participating in This Clinical Trial

Inclusion Criteria

  • Adults and children > 6 years with plaque-type morphea – Subject has not participated in previous study involving imiquimod for three months – In the investigator's judgement, imiquimod treatment may benefit the patient over conventional treatment – Subject has provided informed written consent – Female subjects of childbearing potential have a pregnancy urine test that is negative prior to treatment – Sexually active subjects agree to practice effective birth control throughout the duration of the study Exclusion Criteria:

  • Patients with a non-morphea skin disorder in the region of interest – Subjects previously undergoing morphea therapy within four weeks of the study – Subjects have a known hypersensitivity to imiquimod or component of the cream preparation – Subjects who are pregnant or nursing

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Alberta
  • Collaborator
    • 3M
  • Overall Official(s)
    • Marlene T Dytoc, MD PhD, Principal Investigator, University of Alberta

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.